GERN [NASD]
Geron Corporation
Index- P/E- EPS (ttm)-0.36 Insider Own0.10% Shs Outstand332.07M Perf Week-0.92%
Market Cap707.95M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float- Perf Month16.85%
Income-118.40M PEG- EPS next Q-0.10 Inst Own49.40% Short Float- Perf Quarter51.41%
Sales1.40M P/S505.68 EPS this Y-27.20% Inst Trans0.08% Short Ratio5.30 Perf Half Y102.83%
Book/sh0.29 P/B7.41 EPS next Y0.00% ROA-51.30% Target Price4.20 Perf Year67.97%
Cash/sh0.51 P/C4.25 EPS next 5Y5.00% ROE-84.20% 52W Range0.99 - 2.67 Perf YTD76.23%
Dividend- P/FCF- EPS past 5Y-13.80% ROI-64.70% 52W High-22.48% Beta0.93
Dividend %- Quick Ratio3.80 Sales past 5Y-25.70% Gross Margin- 52W Low109.10% ATR0.18
Employees69 Current Ratio3.80 Sales Q/Q0.00% Oper. Margin- RSI (14)51.38 Volatility8.98% 8.77%
OptionableYes Debt/Eq0.51 EPS Q/Q-5.40% Profit Margin- Rel Volume0.62 Prev Close2.15
ShortableYes LT Debt/Eq0.51 EarningsAug 11 AMC Payout- Avg Volume3.05M Price2.07
Recom1.60 SMA20-0.56% SMA5016.88% SMA20045.72% Volume1,177,019 Change-3.73%
Jul-28-22Resumed B. Riley Securities Buy $4
Nov-02-21Initiated Robert W. Baird Outperform $4
Feb-18-21Resumed B. Riley Securities Buy $4
Aug-03-20Initiated Stifel Buy $3
Nov-19-19Resumed B. Riley FBR Buy $4
Sep-03-19Initiated H.C. Wainwright Buy $4
Aug-15-19Initiated Cantor Fitzgerald Overweight $4
Apr-09-19Upgrade Needham Hold → Buy $3
Jan-31-19Upgrade B. Riley FBR Neutral → Buy $1.50 → $3.25
Oct-02-18Downgrade B. Riley FBR Buy → Neutral $5.75 → $1.50
Jul-05-18Initiated B. Riley FBR, Inc. Buy $5.75
Sep-13-16Reiterated FBR Capital Outperform $6 → $5
Sep-13-16Reiterated FBR & Co. Outperform $6 → $5
Dec-07-15Reiterated Piper Jaffray Overweight $5 → $10
Apr-21-15Initiated Oppenheimer Outperform $5.50
Jun-12-14Upgrade MLV & Co Hold → Buy $2 → $4.25
Mar-12-14Downgrade MLV & Co Buy → Hold $9 → $2
Dec-10-13Upgrade Needham Hold → Buy $10
Dec-10-13Reiterated MLV & Co Buy $8 → $9
Nov-08-13Reiterated MLV & Co Buy $6.50 → $8
Aug-12-22 11:21AM  
Aug-11-22 11:00PM  
05:24PM  
04:05PM  
01:27PM  
Aug-10-22 02:54PM  
Aug-09-22 12:14PM  
12:03PM  
Aug-04-22 04:30PM  
12:00PM  
Aug-03-22 04:30PM  
Jul-21-22 07:05PM  
Jul-13-22 10:18AM  
Jul-08-22 11:44AM  
Jul-07-22 11:30AM  
Jul-01-22 11:01AM  
Jun-30-22 04:15PM  
Jun-29-22 10:28AM  
Jun-28-22 08:49AM  
Jun-27-22 01:21PM  
01:06PM  
Jun-24-22 12:30PM  
Jun-17-22 11:31AM  
09:36AM  
Jun-16-22 04:30PM  
12:15PM  
Jun-15-22 04:10PM  
Jun-13-22 06:13AM  
Jun-10-22 11:57AM  
09:40AM  
Jun-08-22 11:45AM  
May-31-22 09:21AM  
May-30-22 03:10PM  
03:03PM  
May-23-22 12:26PM  
11:46AM  
May-19-22 04:30PM  
12:15PM  
May-17-22 04:30PM  
11:33AM  
11:30AM  
May-10-22 12:21PM  
02:09AM  
May-09-22 05:55PM  
04:05PM  
May-02-22 04:30PM  
May-01-22 08:39AM  
Apr-21-22 04:30PM  
Apr-07-22 05:51AM  
Apr-06-22 04:30PM  
Apr-01-22 04:15PM  
Mar-30-22 05:24PM  
02:25AM  
Mar-29-22 04:01PM  
Mar-17-22 04:30PM  
Mar-10-22 09:00PM  
04:06PM  
Mar-03-22 04:30PM  
Jan-31-22 10:18AM  
Jan-26-22 10:05AM  
Jan-21-22 07:30AM  
Jan-20-22 04:30PM  
Jan-04-22 05:01PM  
Dec-16-21 04:30PM  
Dec-14-21 04:30PM  
Dec-02-21 07:30AM  
Nov-18-21 04:30PM  
Nov-12-21 07:30AM  
Nov-09-21 09:05PM  
06:00PM  
Nov-04-21 09:12AM  
Oct-31-21 10:44AM  
Oct-28-21 03:06PM  
Oct-25-21 04:30PM  
Oct-21-21 04:30PM  
Oct-18-21 07:30AM  
Oct-15-21 04:05PM  
Oct-11-21 04:30PM  
Sep-16-21 04:30PM  
Sep-01-21 04:30PM  
Aug-28-21 08:01AM  
Aug-19-21 04:30PM  
Aug-17-21 08:28AM  
05:00AM  
Aug-16-21 05:25PM  
04:06PM  
Aug-05-21 04:30PM  
Aug-02-21 06:09AM  
Jul-29-21 03:05PM  
Jul-22-21 04:45PM  
Jun-21-21 12:15PM  
08:36AM  
Jun-18-21 11:40AM  
10:04AM  
06:31AM  
Jun-17-21 04:30PM  
Jun-14-21 04:30PM  
May-12-21 10:56AM  
May-11-21 02:01AM  
May-10-21 05:55PM  
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EASTHAM KARINDirectorApr 20Option Exercise1.4135,00049,35074,047Apr 21 08:09 PM